![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 32.75 | 32.50 | 33.00 | 33.00 | 32.75 | 32.75 | 644,278 | 13:04:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 30.8M | -21.7M | -0.0600 | -5.46 | 118.38M |
TIDMCREO
RNS Number : 3290N
Creo Medical Group PLC
23 September 2019
Creo Medical Group plc
("Creo" or the "Company")
Notice of results
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its interim results for the six months ended 30 June 2019 on Monday, 30 September 2019.
Creo Medical Group plc investors.creomedical.com Richard Rees (CFO) +44 (0)1291 606 005 Cenkos Securities +44 (0)20 7397 8900 Stephen Keys / Cameron MacRitchie Michael Johnson / Russell Kerr (Sales) Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893 Lianne Cawthorne Mob: +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiofrequency energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar RF for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes that its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORXXLFLKKFFBBZ
(END) Dow Jones Newswires
September 23, 2019 09:16 ET (13:16 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions